Evidence map›Paper›PMID 37936254›Full record

ReviewExpert review of vaccines

Vaccine development for pathogenic fungi: current status and future directions.

Jéssica L Chechi, Felipe A C da Costa, Julia M Figueiredo, Cássia M de Souza, Alessandro F Valdez, Daniel Zamith-Miranda, Aline C Camara, Carlos P Taborda, Joshua D Nosanchuk

Open access · diamondAbstract readReview
In one paragraph

Review in Expert review of vaccines. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. A comprehensive review of neurotropic fungal infections: clinical manifestations and vaccines.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jéssica L ChechiLaboratório de Fungos Dimórficos Patogênicos, Departamento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, SP, SP, Brazil.
Felipe A C da CostaLaboratório de Fungos Dimórficos Patogênicos, Departamento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, SP, SP, Brazil.
Julia M FigueiredoLaboratório de Fungos Dimórficos Patogênicos, Departamento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, SP, SP, Brazil.
Cássia M de SouzaLaboratório de Fisiologia e Biologia Molecular de Fungos, Departamento de Microbiologia, Universidade Estadual de Londrina, Londrina, Brazil.
Alessandro F ValdezDepartments of Medicine (Division of Infectious Diseases) and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Daniel Zamith-MirandaDepartments of Medicine (Division of Infectious Diseases) and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Aline C CamaraLaboratório de Fungos Dimórficos Patogênicos, Departamento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, SP, SP, Brazil.
Carlos P TabordaLaboratório de Fungos Dimórficos Patogênicos, Departamento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, SP, SP, Brazil.
Joshua D NosanchukDepartments of Medicine (Division of Infectious Diseases) and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Universidade de São Paulo · BRAlbert Einstein College of Medicine · USUniversidade Estadual de Londrina · BR

Funding

The biology of Cryptococcus neoformans melanizationR01AI171093 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Arturo Casadevall, JOSHUA D NOSANCHUK · 2023 to 2026
$3.2M
Development and optimization of a nitric oxide releasing microparticle-basedtopical treatment for onychomycosisR41AI165204 · NIAID · ZYLO THERAPEUTICS, INC. · PI DRAGANSKI, ANDREW R, NOSANCHUK, JOSHUA D · 2022 to 2023
$600k
Antibody differentially alters Histoplasma extracellular vesiclesR21AI124797 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI NOSANCHUK, JOSHUA D · 2016 to 2017
$538k
NIAID NIH HHS R01 AI171093NIAID NIH HHS R21 AI124797NIAID NIH HHS R41 AI165204
6 · The paper itself

Abstract

introductionFungal infections are caused by a broad range of pathogenic fungi that are found worldwide with different geographic distributions, incidences, and mortality rates. Considering that there are relatively few approved medications available for combating fungal diseases and no vaccine formulation commercially available, multiple groups are searching for new antifungal drugs, examining drugs for repurposing and developing antifungal vaccines, in order to control deaths, sequels, and the spread of these complex infections. AREAS COVERED: This review provides a summary of advances in fungal vaccine studies and the different approaches under development, such as subunit vaccines, whole organism vaccines, and DNA vaccines, as well as studies that optimize the use of adjuvants. We conducted a literature search of the PubMed with terms: fungal vaccines and genus of fungal pathogens (Cryptococcus spp. Candida spp. Coccidioides spp. Aspergillus spp. Sporothrix spp. Histoplasma spp. Paracoccidioides spp. Pneumocystis spp. and the Mucorales order), a total of 177 articles were collected from database. EXPERT OPINION: Problems regarding the immune response development in an immunocompromised organism, the similarity between fungal and mammalian cells, and the lack of attention by health organizations to fungal infections are closely related to the fact that, at present, there are no fungal vaccines available for clinical use.

Indexed as

MycosesVaccinesAnimalsAntifungal AgentsFungiHumansMammalsVaccine DevelopmentAntifungal AgentsVaccinesfungal biologyFungal vaccineimmune therapyprophylactic vaccinesubunittherapeutic vaccine

Identifiers

PMID37936254
PMCPMC11500455
OpenAlexW4388497063

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.